Company news

Share this article:
Pfizer announced that it has entered into a $15 million dollar collaboration with the University of Pennsylvania School of Medicine. The partnership will include collaborations between Pfizer and the university in the areas of scientific research, clinical development and clinical care and policy. Under the terms of the agreement, Pfizer will pay Penn $15 million over a three-year period, during which time scientists from Pfizer and Penn's School of Medicine will work together on several projects of mutual interest including basic and translational research addressing several therapeutic areas. Project proposals will be solicited and reviewed by a committee with representation from both parties. The initial emphasis of the collaboration will focus on the neurosciences and oncology, but may expand to other areas, Pfizer said in a statement.

Omnicom's digital and CRM-intensive STAR Marketing network launched a healthcare offering. STAR Healthcare will offer “integrated, personalized” direct to patient programs under the guidance of managers to be announced in two unique positions: those of “patient advocate” and “client champion.”

Ketchum launched Well Connected, a “cross-practice health and wellness specialty” aimed at leveraging the shop's expertise in health and wellness, influencer relationships and proprietary research in food and nutrition, healthcare and brand. In addition to research, the practice also offers clients a partnership with the National Senior Games Association and supermarket and branding expert Phil Lempert.  
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.